Christopher Black

Nov 11, 2024 | onlinelibrary.wiley.com | Isabel Carbery |Oliver Todd |Matthew Hale |Christopher Black

Data Availability Statement The data underlying this paper are available in the paper and in the Supporting Information.

Jul 4, 2024 | onlinelibrary.wiley.com | Christopher Black

Disorders of gut-brain interaction (DGBI), such as irritable bowel syndrome and functional dyspepsia, are common worldwide and are more prevalent among younger individuals.1 However, they may also affect older people.

Jun 2, 2023 | nature.com | Heidi M Staudacher |Christopher Black

AbstractIrritable bowel syndrome (IBS) affects 5–10% of the global population. Up to one-third of people with IBS also experience anxiety or depression. Gastrointestinal and psychological symptoms both drive health-care use in people with IBS, but psychological comorbidity seems to be more important for long-term quality of life. An integrated care approach that addresses gastrointestinal symptoms with nutrition and brain–gut behaviour therapies is considered the gold standard.

Feb 27, 2023 | shorturl.at | Christopher Black |Alexander Ford

Some patients with irritable bowel syndrome (IBS) demonstrate low-grade inflammation in the intestine. Mesalamine, which has anti-inflammatory effects, may be an efficacious treatment for IBS, but studies are conflicting. We conducted a systematic review and meta-analysis to assess efficacy and safety of mesalamine in IBS. We searched the medical literature up to September 14, 2022, to identify randomized controlled trials (RCTs) of mesalamine in IBS.